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Introduction
Cancer is the second most common cause of death among adults [1] . This is often because of late-stage presentation such that metastases are present at diagnosis. Local surgical therapy and chemotherapeutic regimens are variably effective and both are limited by the side effects or morbidity of their uses. Late-stage presentation coupled with ineffective therapy results in inadequate long-term survival. This concept is well illustrated by pancreatic cancer, in which surgery is only partially effective in early-stage patients, chemotherapy is limited by systemic toxicity, and overall survival is approximately 5% [2] . These data indicate the dramatic need for development of novel targeted therapeutics if we are going to improve survival for patients with cancer in all realms of the disease.
One class of targeting agents under intense development is antibodies and engineered antibody fragments ( Fig. 1 ). Antibodies are a unique class of targeting agents capable of exquisite specificity for cell surface antigens. The smallest engineered antibody fragment that retains antigen specificity is the single-chain Fv (scFv) fragment consisting of a variable light chain and a variable heavy chain joined by an amino acid linker [3] . The length of the linker sequence can be adjusted to promote the formation of the diabody, a noncovalent dimer of two scFv fragments [4, 5] . The diabody format has been shown to exhibit superior binding affinity and avidity compared with the scFv, likely because of its bivalency for its antigen [6] . Moreover, a covalent dimer of two scFv fragments (cys-diabody) can be created by engineering C-terminal cysteine residues into the DNA construct of the scFv [7] . The cys-diabody has the ability to be site specifically conjugated with fluorophores or radioisotopes through the free sulfhydryl groups of the cysteine residues after reduction of the disulfide bond [7] . The work by Carmichael et al. [8] elucidated the crystal structure of the anti-Carcinoembyonic antigen diabody and showed that the C-termini are at the opposite end of the protein's antigen-binding pocket, making it an appealing site to engineer the cysteine residues. This study further suggested that modification in this manner should not alter the diabody's affinity once labeled to a radionuclide through those cysteine residues [8] . The unique ability to conjugate site specifically to these cysteine residues makes the cys-diabody fragment an attractive fragment for therapeutic applications. In particular, it can be used for site-specific conjugation of therapeutic nanoparticles and thus have the potential to deliver targeted therapy to cancer cells.
Nanoparticles are an emerging class of delivery vehicle for traditional cytotoxic chemotherapeutics with the promise of delivering higher concentrations of chemotherapeutics to the tumor tissue relative to normal tissues [9] . They are easy to prepare in a variety of sizes, are biocompatible, and can carry a wide variety of therapeutics. Additionally, the surfaces of nanoparticles can be easily modified, allowing the potential to perform a myriad of chemical reactions on the nanoparticle surface. Currently, Food and Drug Administration approved that nanoparticles accumulate into tumor tissue through the highly permeable blood vessels of tumors as a result of defective angiogenesis and tend to be retained in tumor tissues because of poor lymphatic drainage. This mechanism known as enhanced permeability and retention guides the accumulation of nanoparticles without necessitating specific tumor targeting [10] . However, this mechanism is still limited by nonspecific uptake into normal tissues. To circumvent this problem and more effectively target nanoparticles to cancer cells minimizing systemic toxicity, nanoparticles have the potential to be chemically conjugated to a tumor-targeting agent, such as the cys-diabody, for antigen-specific localization to tumor cells.
Liposomes in general are one of the most versatile and safe nanoparticles to be applied to cancer chemotherapeutics, owing to their ease of preparation, compatibility with a wide variety of drugs and biomolecules, large carrying capacity, and facile surface coating by targeting or immune system avoidance molecules [11] . An improvement to conventional liposomes is the polymerized liposomal nanoparticles (PLNs) formed from cross-linking polymerized diacetylene lipids. They are of uniform and specified size, are stable, can be reliably produced and modified on the surface (e.g., polyethylene glycol) to render them biocompatible, and can be coated with a tumor-targeting agent. In this regard, they do not elicit an immune response and can target cells, be internalized, and deliver a cytotoxic payload.
Previously, our group evaluated the ability to target the carbohydrate antigen 19-9 (CA19-9) with radiolabeled antibodies in xenograft models of pancreatic cancer [12] . Specifically, we created an anti-CA19-9 diabody that demonstrated good antigen-specific tumor targeting. CA19-9 is a sugar epitope presented on the cell surface proteins of pancreatic cancer cells secondary to aberrant glycosylation of proteins on malignant transformation of epithelial cells. CA19-9 has distinct advantages as a tumor target because of its location on the outermost extent of the cell surface and its abundance. Therefore, the goal of this study was to modify the anti-CA19-9 diabody by engineering cysteine residues into the protein, characterize the newly generated cysteine-modified anti-CA19-9 diabody (anti-CA19-9 cys-diabody), and confirm its ability to retain its targeting potential by itself and while conjugated to PLNs. To do this, we first engineered the cysteine residues into the C-terminus of the anti-CA19-9 diabody and evaluated its antigen-specific binding ability in vitro and in vivo using microepositron emission tomography (micro-PET)/microecomputed tomography (micro-CT). Next, we conjugated the anti-CA19-9 cys-diabody to the surface of the nanoparticle via the free sulfhydryl groups of the reduced cysteine residues. Finally, we evaluated the ability of the anti-CA19-9 cys-diabodyePLN conjugate to discriminate CA19-9epositive cells from negative cells using immunofluorescence studies and flow cytometry.
Methods

Materials
PLNs were obtained from NanoValent Pharmaceuticals, Inc (Bozeman, MT). The lipids comprising the PLNs are N-(5 0 -hydroxy-3 0 -oxypentyl)-10,12-pentacosadiynoic acid (h-Peg 1 -PCDA), N-[methoxy(polyethylene glycol)-750]-10,12pentacosadiynoic acid (m-Peg 750 -PCDA), N-(5 0 -sulfo-3 0oxypentyl)-10,12-pentacosadiynoic acid (sulfo-Peg 1 -PCDA), sodium salt, and N-[maleimide(polyethylene glycol)-1500]-10,12-pentacosadiynoic acid (mal-Peg 1500 -PCDA).
2.2.
Construction of the anti-CA19-9 cys-diabody
The scFv DNA fragment in the pUC18 vector (New England Biolabs, Beverly, MA) engineered previously for the anti-CA19-9 diabody was used as the template to perform polymerase chain reaction (PCR) mutagenesis and add the cysteine residues into the C-terminal end of the scFv [13] . This was accomplished using standard PCR components (Invitrogen, Carlsbad, CA) with a 48 bp primer to insert the GGCGG amino acid sequence (5 0 -GAATTCTCAATGATGATGATGATGATGA CCCCCACACCCACCTGCAGA-3 0 ; IDT Integrated DNA Technologies, San Diego, CA). This construct was confirmed by DNA sequencing, excised from the pUC18 vector, and ligated into the pEE12 mammalian expression vector (Lonza Biologics, Slough, United Kingdom) containing the glutamine synthetase gene for selection and the hCMV promoter for high expression [14] .
Expression, selection, and purification
NS0 murine myeloma cells (5.0 Â 10 6 ) were transfected by electroporation with 20 mg of linearized pEE12 cys-diabody DNA construct. Cells were selected in glutamine-deficient Dulbecco's Modification of Eagle's Medium (DMEM) or high modified media (JRH Biosciences, Lenexa, KS) as previously described [15, 16] . Transfectants were screened for the expression of cys-diabody by Western blot analysis, in which the nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA) was incubated sequentially with 0.1 mg/mL of antiepenta-His immunoglobulin G (IgG) antibody (Sigma-Aldrich, Bellefonte, PA) and 0.1 mg/mL of alkaline phosphatase (AP)e conjugated goat anti-mouse IgG, Fc-specific antibody (Jackson ImmunoResearch Labs, West Grove, PA) and developed with BCIP/NCP Color Development Substrate (Promega, Madison, WI). Based on the Western blot analysis, high-producing clones were selected for expansion into triple flasks (Nunclon, Rochester, NY). After cell growth and exhaustion in the triple flask stage, the supernatant was harvested and centrifuged to remove cellular debris and then applied onto a 1-mL HiTrap Chelating HP column (GE Healthcare, Piscataway, NJ) at a flow rate of 1 mL/min using an AKTA Purifier (GE Healthcare) for cys-diabody purification. Bound proteins were eluted with 250 mM imidazole in phosphate-buffered saline (PBS). Fractions containing the cys-diabody were evaluated with sodium dodecyl sulfateepolyacrylamide gel electrophoresis (SDS-PAGE), pooled, and dialyzed against PBS using a Slide-A-Lyzer Dialysis Cassette (Thermo Fisher Scientific, Rockford, IL) with a molecular weight cutoff of 10,000 Da to buffer exchange the purified protein. The purified and buffer exchanged cys-diabody was then concentrated using a spin column (Vivaspin 20, 10 kDa cutoff; Thermo Fisher Scientific), and the final cys-diabody protein was stored at 4 C.
Biochemical characterization of purified anti-CA19-9 cys-diabody protein
The purified anti-CA19-9 cys-diabody was analyzed with SDS-PAGE on precast 4%e20% gels (Bio-Rad Laboratories). Protein samples were incubated with and without the reducing agent, dithiothreitol, at a concentration of 100 mM of dithiothreitol to ensure efficient reduction of the disulfide bond. Gels were stained with Microwave Blue (Protiga Inc, Frederick, MD) for the detection of proteins. Samples were also analyzed with size-exclusion chromatography on a Superdex 75 HR 10/30 column (GE Healthcare). Approximately 50 mg of protein was applied to the column and run isocratically in PBS at a flow rate of 0.5 mL/min on the AKTA Purifier. Elution time was obtained and compared with carbonic anhydrase (30 kDa) and bovine serum albumin (66 kDa) standards (Sigma-Aldrich).
2.5.
Cell lines NS0 mouse myeloma cells were maintained with DMEM or high modified media supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% glutamine (Invitrogen). The human pancreatic cancer cell lines, such as BxPC3 and MiaPaca-2 (American Type Culture Collection, Manassas, VA), were maintained in Roswell Park Memorial Insitute-1640 and DMEM, respectively. All media were supplemented with 1% penicillin or streptomycin (Invitrogen) and 10% FBS. Media for the MiaPaca-2 cell line were also supplemented with 2.5% horse serum (Invitrogen) as recommend by the American Type Culture Collection.
Preparation of PLNs
Liposomes were prepared from h-Peg 1 -PCDA, m-Peg 750 -PCDA, sulfo-Peg 1 -PCDA, and mal-Peg 1500 -PCDA (molar ratio of 6.7:2.6:0.5:0.2) according to the method previously described [17] . Briefly, lipids were mixed and evaporated in vacuo to a film. Deionized water was added to the films so as to give a 24 mM (total lipid) suspension. The suspension was heated via sonication between 70 C and 80 C with a probe-tip sonicator (Fisher sonic dismembrator model 300, Fisher Scientific) for 10 min. The resulting clear solution was then cooled to 5 C for 20 min, warmed to ambient temperature for 20 min, and polymerized by UV light irradiation (254 nm) with a Spectrolinker XL-1000 UV Crosslinker (Spectronics Corp, Lincoln, NE) for 10 min. The resulting blue PLNs were heated to 65 C for 5 min to convert them to the red (fluorescent) form. The colored solutions were syringe filtered through 0.2 mm cellulose acetate filters to remove trace insoluble contaminants. The average particle size measurements were obtained on a Zetasizer Nano-S (Malvern Inst, Worcestershire, UK) in a solution of 10 mM sodium chloride.
2.7.
Conjugation of the anti-CA19-9 cys-diabody to PLNs
The anti-CA19-9 cys-diabody was conjugated to PLNs using maleimide chemistry. Approximately, 50 mg of cys-diabody in 50 mL of PBS was reduced with 100 mL of immobilized tris (2-carboxyethyl) phosphine (Thermo Fisher Scientific) for 30 min at room temperature. The tris (2-carboxyethyl) phosphine was subsequently spun out of solution in a cellulose spin cup (Thermo Fisher Scientific). The reduced cys-diabody was added immediately to a solution of PLNs (NanoValent Pharmaceuticals, Inc) at a ratio of 50 mg of cys-diabody to 250 mg of PLNs. This mixture was incubated at room temperature for 2 h and dialyzed overnight in PBS buffer using Slide-A-Lyzer Dialysis Cassette (molecular weight cutoff, 100 kDa, Sartorius Stedim Biotech, Goettingen, Germany) to remove any free unbound cys-diabody.
2.8.
In vitro binding assays by flow cytometry and immunofluorescence Flow cytometry and immunofluorescence were used to assess the binding ability of both the anti-CA19-9 cys-diabody and the anti-CA19-9 cys-diabodyePLN conjugate. All human pancreatic cell lines were harvested (1 Â 10 6 cells), resuspended in 250 mL of PBS with 2% FBS, and incubated with 4 mg of cys-diabody on ice for 1 h. The cells were washed for 10 min by centrifugation at 1000 Â g, the supernatant was discarded, and the cells were resuspended in another 250 mL of PBS with 2% FBS. The cells were again incubated with secondary antibody, 4 mg of antiepenta-His IgG antibody (Sigma-Aldrich), for 1 h on ice. Another wash was performed, and the cells were finally incubated for 1 h on ice with 4 mg of tertiary antibody, R-phycoerythrineconjugated goat anti-mouse IgG, Fc-specific antibody (Jackson Immunoresearch Labs). A final wash was performed, and the cells were resuspended with 500 mL PBS with 2% FBS. Binding data were obtained using a ScanX flow cytometer (Becton Dickinson, Franklin Lakes, NJ) and analyzed using FlowJo software (Tree Star Inc, Ashland, OR).
Similarly, immunofluorescence was performed using sixwell plates (Becton Dickinson) with sequential incubation steps of the anti-CA19-9 cys-diabody, secondary antibody, and tertiary antibody with wash steps in between incubations. On completion of all steps, the wells were visualized with a Nikon 90S fluorescent microscope (Nikon Inc, Melville, NY), and images were taken with a 5.1 megapixel CCD camera (Nikon). Fluorescent images were generated with a white light X-Cite 120Q source (Scientifica, East Sussex, UK), using an excitation wavelength bandpass filter of 545e565 nm and an emission wavelength bandpass filter of 580e620 nm. All images were obtained using a magnification lens of 20Â. Images were analyzed using Nikon software and were processed for contrast and brightness using Photoshop Elements 4 (Adobe Systems Inc, San Jose, CA).
For both flow cytometry and immunofluorescence, negative control samples included those with cells only or cells incubated with the secondary and tertiary antibodies and no primary antibody. Experimental samples included those with cells incubated with the cys-diabody, secondary, and tertiary antibodies. The positive control samples included those with cells incubated with the parental intact monoclonal antibody (mAb) and tertiary antibody.
Additionally, flow cytometry and immunofluorescence were performed in the same manner using the anti-CA19-9 cys-diabodyePLN conjugate as the primary antibody. Because the PLN exhibits autofluorescence within the same wavelength excitation and emission range as R-phycoerythrin, no secondary and tertiary antibodies were used. Experiments included cells only, cells incubated with cys-diabodyePLN conjugate, and cells incubated with PLNs only as a negative control.
2.9.
Cell-based competition enzyme-linked immunosorbent assay
To determine the relative binding affinity of the anti-CA19-9 cys-diabody, a cell-based competition enzyme-linked immunosorbent assay was performed. CA19-9epositive cells, BxPC3, were harvested, counted, and aliquoted into a 96-well plate (50,000 cells per well) for adhesion overnight. The following day, the cell media were removed, and each well was washed with 150 mL of PBS and 2% FBS. The wash was also removed, and each well was incubated for 1 h at room temperature with 150 mL of a 1 nM concentration of the parental intact anti-CA19-9 mAb obtained from purifying the supernatant of the 116-N-19-9 hybridoma cells known to produce the mAb [18] . After incubation, the wells were washed similarly and incubated for 1 h at room temperature with 150 mL of varying concentrations, ranging from 0.01 to 100 nM, of the anti-CA19-9 cys-diabody. Again, the wells were washed and incubated with 150 mL of a 1:2500 mL dilution of AP-conjugated goat anti-mouse IgG, Fc-specific antibody (Jackson Immunoresearch Labs). After 1 h, the wells were washed again and developed with 150 mL of a solution of 10 mg phosphatase tabs (Sigma-Aldrich) dissolved in 10 mL of AP buffer. The reaction was permitted to proceed for 15 min and then evaluated for absorbance at 405 nm using the GENios microplate reader (Tecan, Durham, NC). All experiments were done in triplicate. A saturation binding plot was created based on the absorbance value of each sample to calculate the dissociation constant (K d ), defined as the amount of cys-diabody needed to displace 50% of the parental intact anti-CA19-9 mAb.
Radioiodination
Radiolabeling of the anti-CA19-9 cys-diabody with the positron-emitting isotope, iodine-124 ( 124 I), was performed using the iodogen method as described [19] using Pierce Pre-Coated Iodination Tubes (Thermo Fisher Scientific). The labeling reaction was performed with 200 mg of purified cysdiabody (200 mL) and 800 mCi of Na 124 I (IBA Molecular, Dulles, VA). Instant thin layer chromatography using the Tec-Control kit (Biodex Medical Systems, Shirley, NY) was used to measure labeling efficiency. Immunoreactivity, defined as the fraction of cys-diabody retaining the ability to bind to cells after radiolabeling, was determined by incubating the radioiodinated cys-diabody (z100,000 cpm) with BxPC3 and MiaPaca-2 cells in 1 mL of PBS and 2% FBS such that there was an excess of antigen for the positive cell line. The radioiodinated cysdiabody was allowed to incubate with the cells for 1 h at room temperature, after which the cells were centrifuged at 800 g for 5 min. The supernatant was removed and collected; the cell pellet was then resuspended in 1 mL of PBS and 2% FBS and collected. The radioactivity in the supernatant and cell pellet was measured in a Wizard 3 0 1480 Automatic Gamma Counter (Perkin-Elmer, Covina, CA). The radioactivity in the cell pellet (bound cys-diabody) was divided by the total radioactivity in the cell pellet plus the supernatant (unbound cys-diabody), yielding the fraction of bound cys-diabody. This fraction was multiplied by 100 yielding the percentage of immunoreactivity.
Xenograft imaging and biodistribution studies
Animal handling was carried out under a protocol approved by the Chancellor's Animal Research Committee of the University of California in Los Angeles (UCLA). The antigenpositive (BxPC3) xenograft models were established with 1 Â 10 6 cells injected subcutaneously into the left shoulder of four female nude mice (Charles River Laboratories, Wilmigton, MA). In the same four mice, the antigen-negative cell line (MiaPaca-2) was injected in the right shoulder as a negative control. Tumors were allowed to develop for approximately 3 wk. Gastric lavage was performed with 1.5 mg of potassium perchlorate in 200 mL of PBS at 30 min before tail vein injection of 124 I-anti-CA19-9 cys-diabody. Additionally, blocking of thyroid uptake of radioiodine was accomplished by adding saturated potassium iodide (0.5 mL/100 mL of water) to the drinking water 24 h before injection of the radioiodinated cysdiabody. Mice were injected with approximately 25 mg of 124 Ianti-CA19-9 cys-diabody (specific activity of 4.03 AE 1.8 mCi/mg) in PBS and 2% FBS via the tail vein. Micro-PET was performed at 4 and 20 h after injection. These time points for imaging were chosen based on previously measured half-lives of diabody fragments and corresponded to approximately one half-life and five half-lives, respectively [7, 20, 21] . Also, to appropriately compare the in vivo targeting ability of the anti-CA19-9 cys-diabody to the anti-CA19-9 diabody, we performed the imaging experiments at the same time points as previously published for the anti-CA19-9 diabody [12] . The mice were anesthetized using 2% isoflurane, placed on the micro-PET bed, and imaged with a Focus micro-PET scanner (Concorde Microsystems Inc, Knoxville, TN). Acquisition time was 10 min. All images were reconstructed using a FBP algorithm and displayed by the AMIDE software package [22, 23] . One mouse was subsequently imaged with micro-CT, and the micro-CT images were coregistered with the micro-PET images to provide an anatomic reference. Animals were euthanized after the last imaging time point, and organs, tumors, and blood were harvested and weighed. Radioactive uptake of organs was counted in a gamma counter for biodistribution analysis and converted to a percentage of injected doses of radioactivity per gram of tissue after decay correction.
Results
Construction of the anti-CA19-9 cys-diabody
Using the anti-CA19-9 diabody DNA as a template, PCR mutagenesis was performed to insert the C-terminal cysteine residues. Gene sequencing and comparison with the published sequence confirmed success [24] .
Expression, selection, and purification
The cys-diabody was expressed in NS0 myeloma cells. Cell culture supernatant was harvested and analyzed with Western blot analysis to determine those clones expressing the highest levels of protein. These were selected for expansion into triple flasks (Nunclon). Selected clone expression ranged from 10 to 45 mg/L. The 6ÂHis tag engineered on the C-terminus of the anti-CA19-9 cys-diabody was used for protein purification. Approximately 100 mL of the culture supernatant yielded 1e4.5 mg of pure protein.
Biochemical characterization of the anti-CA19-9 cys-diabody
The protein purity of the isolated cys-diabody obtained from metal affinity chromatography was confirmed by SDS-PAGE and Western blot analysis ( Fig. 2A and B) . Size-exclusion chromatography was done to evaluate for the presence of the appropriate covalent interactions between two scFv fragments to form the cys-diabody (Fig. 2C ). As shown, compared with bovine serum albumin (20.75 min) and carbonic anhydrase (24.75 min) standards, the cys-diabody elution time was 23.98 min. The elution time of the cys-diabody was consistent with its predicted molecular weight of 55 kDa.
3.4.
In vitro binding assays for the characterization of the anti-CA19-9 cys-diabody CA19-9 recognition and binding were evaluated by flow cytometry and immunofluorescence. The anti-CA19-9 cysdiabody demonstrated the ability to distinguish between the CA19-9epositive cell line, BxPC3, and the CA19-9enegative cell line, MiaPaca-2, by flow cytometry (Fig. 3A) . The cys-diabody exhibited slightly lower binding efficiency compared with the parental intact anti-CA19-9 antibody. MiaPaca-2 showed no expression of CA19-9 and served as the negative control. Immunofluorescence data were in accordance with the flow cytometry data (Fig. 3B) . The MiaPaca-2 cell line showed no binding of the cys-diabody, whereas the BxPC3 cell line showed binding of the cys-diabody to the cells in vitro.
3.5.
Cell-based competition enzyme-linked immunosorbent assay
A competition binding assay as described was performed to ascertain the relative binding affinity of the anti-CA19-9 cysdiabody compared with the murine anti-CA19-9 intact antibody. The absorbance values obtained for each sample were averaged and plotted on a saturated binding plot. The observed relative binding affinity of the diabody was approximately 6 nM (Fig. 3C ).
Radioiodination, xenograft imaging, and biodistribution studies
In vivo tumor targeting of the anti-CA19-9 cys-diabody was evaluated with micro-PET imaging. Nude mice carrying CA19-9epositive (BxPC3) and CA19-9enegative (MiaPaca-2) tumors were injected with the 124 I-labeled anti-CA19-9 cys-diabody. The labeling efficiency of 124 I on the anti-CA19-9 cys-diabody was 96%. Immunoreactivity of the 124 I-labeled anti-CA19-9 cys-diabody on BxPC3 and MiaPaca-2 cells was 75% and 1%, respectively. Micro-PET imaging studies were conducted in four animals bearing BxPC3 tumors averaging 36 mg (range, 9e67 mg) and MiaPaca-2 tumors averaging 29 mg (range, 21e39 mg) and obtained at 4 and 20 h after injection of the cysdiabody. Figure 4 illustrates representative images from each study. After the 20-h time point, all four mice were sacrificed and organs were harvested for measurement of radioactivity to provide quantitative evidence of tumor targeting. These data were used to calculate tumor-to-blood ratios in each animal. For the four mice bearing BxPC3 tumors, the positive tumor activity averaged 1.1% ID/g with a range of 0.4e1.7% ID/ g. The average negative tumor activity in this model was 0.2% ID/g (range, 0.1e0.3% ID/g). The difference in percentage of injected doses of radioactivity per gram between the positive tumor and the blood trended toward but did not reach significance (P ¼ 0.077); however, the difference between the positive and the negative tumors (P ¼ 0.043) was able to reach significance as determined by paired t-test. The average tumor-to-blood ratio was 2.7:1, and the positive-to-negative tumor ratio was 6:1. High uptake was noted in the liver (data not shown).
Construction of maleimide PLNs and characterization
PLNs were synthesized by the self-assembly of lipids into small unilamellar liposomes. The polymerizable lipids contain diacetylene groups in the fatty acid tails. Methoxy-and maleimide-terminated polyethylene glycol polymers are appended to the liposome-forming lipids by chemically conjugating them to the carboxyl groups in the commercially available pentacosadiynoic acid lipid (GFS Chemicals, Powell, OH). Aqueous dispersions of the lipids are sonicated while being heated to a temperature above the lipid phase transition giving liposomes that appear as clear solutions. To obtain PLNs (polydiacetylene), the lipid chains must be in a tightly packed solid analogous state as part of the membrane bilayer [25] . This is achieved by cooling the liposome solution to 5 C for 20 min. After warming, the solutions are irradiated with UV light to initiate a radical polymerization process, resulting in a deeply blueepurple colored PLN solution.
The blueepurple form of the PLN is only slightly fluorescent, and to obtain highly fluorescent particles, the solutions are briefly heated. This results in a slight perturbation of the polydiacetylene polymer backbone that results in a chromatic shift in color and fluorescence [26, 27] . The fluorescence emission spectrum is centered at 635 nm with a broad and complex excitation spectrum from 480 to 580 nm. We have seen some evidence that cellular uptake of the nonfluorescing PLNs rapidly converts them into fluorescent form (unpublished data). For the cell uptake studies, however, we preheated the PLNs to convert them all into their fluorescent form. A distinct advantage to the PLN fluorescence is that little or no photobleaching occurs.
The PLNs resulting from simple probe-tip sonication of this lipid formulation give a fairly tight population of small-sized particles. Particle size analysis shows them to be typically in a size range from 30 to 50 nm, with the average size centering around 38 nm. No attempts were made to produce tighter size ranges by membrane extrusion, although this technique is applicable to the liposome preparation step and will be conducted for material that will subsequently be administered in vivo in future studies.
3.8.
Conjugation of the anti-CA19-9 cys-diabody to PLNs Approximately 200 mg of anti-CA19-9 cys-diabody was used for conjugation to 1000 mg of PLNs (Fig. 5 ). The reaction time was 2 h. Reaction efficiency was approximately 80% measured by calculation of the amount of cys-diabody remaining after buffer exchange. Additionally, this conjugation reaction demonstrated storage stability at 4 C as all experiments were duplicated 1 mo after conjugation with similar results.
3.9.
In vitro binding assays for characterization of the anti-CA19-9 cys-diabodyePLN conjugate Flow cytometry of the anti-CA19-9 cys-diabodyePLN conjugate displayed similar results compared with that of the unconjugated anti-CA19-9 cys-diabody (Fig. 6) . The fluorescent nature of the PLN allowed the cys-diabodyePLN conjugate to discriminate between the positive and the negative cell lines by both immunofluorescence and flow cytometry. The lack of a fluorescent secondary antibody confirms that the cys-diabodyePLN conjugation is the only source of fluorescence; therefore, the presence and localization of the fluorescent PLN demonstrate continued conjugation of the PLN to the antigen-specific cys-diabody. Furthermore, immunofluorescence of the cys-diabodyePLN conjugate demonstrated a pattern of localization to the outer surface of the cell membrane ( Fig. 6 ).
Discussion
Previously, we investigated the potential of an anti-CA19-9 diabody to target pancreatic cancer xenografts in a mouse model [12] . CA19-9 was chosen because of its prevalence on >90% of all pancreatic cancers and its accessibility on the outer surface of cell membranes [28e31] . In addition to its widespread prevalence and accessibility, it is very abundant with expression estimated to be between 1 and 2 million antigens per cell. Based on these attributes, it represents an ideal tumor target. With the anti-CA19-9 diabody, we were able to demonstrate targeting of CA19-9 in vitro and in vivo [12] . These results encouraged us to modify the diabody to a cysdiabody and exploit the unique ability to site specifically conjugate to this fragment. To this end, we engineered, produced, and characterized the anti-CA19-9 cys-diabody. We show that our cys-diabody exhibits similar biochemical properties to other engineered cys-diabodies, displaying a molecular weight of 55 kDa and forming a covalent dimer [7, 13] . In addition, we demonstrate specific binding of CA19-9 with the cys-diabody by flow cytometry and immunofluorescence with similar binding affinity compared with the parental anti-CA19-9 diabody.
To ensure that the modification of C-terminal cysteine residues did not alter the in vivo binding properties of the diabody, we investigated the ability of the cys-diabody to target CA19-9 by injecting mice harboring the BxPC3 and MiaPaca-2 xenografts via the tail vein with 124 I-labeled anti-CA19-9 cys-diabody. Micro-PET images at 4 h demonstrated quick targeting of the antibody fragment to the BxPC3 xenograft (CA19-9 positive), similar to the parental anti-CA19-9 diabody. Additionally, we showed that the cys-diabody was retained at the site of the xenograft based on the persistence of signal on micro-PET images at the 20-h time point. Biodistribution data, corrected for time of injection, provided raw numerical values expressed in percentage of the injected doses of radioactivity per gram of tissue and was ascertained for the positive tumors, negative tumors, blood, and organs. The positive tumors demonstrated an average of 1.1% ID/g and a positive tumor-to-blood ratio of 2.7:1, which is consistent with the parental anti-CA19-9 diabody values of 1.1% ID/g and ratio of 5:1 previously published by our group [12] . As expected, the liver demonstrated a high percentage of injected doses of radioactivity per gram accounting for the presence of signal in the liver on micro-PET images. This phenomenon is explained best by Ahlgren et al. [32] who characterized a Her2 affibody with and without a 6ÂHis tag noting that the affibody with the 6ÂHis tag had significantly increased amount of liver uptake compared with the Her2 affibody without the tag. Although this phenomenon has not been specifically described in humans, it represents a potential obstacle to clinical translation of proteins engineered with 6ÂHis tags and can be overcome with alternate purification techniques not requiring the 6ÂHis tag. More importantly, a tumor-to-blood ratio of 2.7:1 and a positiveto-negative tumor ratio of 6:1 were obtained. These values indicate that the images display enough contrast between the tumor and the blood (i.e., background) to be visualized. Not only do these data indicate antigen-specific targeting of the BxPC3 xenograft but also provide evidence of the potential of the anti-CA19-9 cys-diabody as a targeting agent for pancreatic cancer.
After confirming the cys-diabody's ability to antigen specifically target CA19-9epositive cells both in vitro and in vivo, we set out to develop a site-specific conjugation reaction to add our anti-CA19-9 cys-diabody to the surface of our PLNs. By reducing the disulfide bonds of the C-terminal cysteine residues, free sulfhydryl groups are available for conjugation to PLNs using maleimide chemistry. The maleimide group was incorporated onto the PLN surface right from the assembly stage by attaching it to one of the PLN-forming lipids. To confirm that the cys-diabodyePLN conjugate was created and that it bound to cells in an antigen-specific manner, we conducted a number of studies. Given the PLN's inherent autofluorescence, we assumed that a cell with PLN bound would be captured by the flow cytometry detector without any additional method of detection [33] . The negative cell line showed no fluorescence with the PLN alone or with the conjugate solution, and the BxPC3 cells demonstrated fluorescence only with the cys-dia-bodyePLN conjugate and not with the PLN alone. These results confirm that the conjugation reaction was successful and that we are able to target PLNs to cancer cells in vitro through the specific antibodyeantigen interaction of the anti-CA19-9 cys-diabody.
This achievement further defines the potential to deliver targeted treatment to cancer cells. By virtue of the ability of PLNs to serve as vehicles for chemotherapeutic agents, this could provide a method by which our targeting agent, the anti-CA19-9 cys-diabody, can be applied for delivery of targeted therapy. Although further studies evaluating the ability of the cys-diabodyePLN conjugate to target pancreatic cancer and other cancers in vivo need to be performed, the potential for an antigen-specific technique for delivery of chemotherapeutics is promising.
Conclusions
Diabodies are small bivalent antibody fragments that are highly specific agents that can be used to target tumor antigens. In this study, we expand on our previous results with the anti-CA19-9 diabody by engineering the anti-CA19-9 cys-diabody to exploit its ability to be site specifically conjugated to PLNs. After modifying the diabody to the cys-diabody, we show that the antibody fragment retains its antigen specificity in vitro and in vivo providing antigen-specific micro-PET imaging of pancreatic cancer xenografts in a mouse model. Additionally, we demonstrated that the cys-diabody can be covalently conjugated to PLNs while retaining its immunoreactivity against the tumor antigen CA19-9. This report using sitespecific conjugation of a cys-diabody to a nanoparticle opens the door to a wide variety of possible therapeutic and diagnostic applications because of the flexible nature of these liposomal vehicles. Passive targeting via the enhanced permeability and retention effect may not be sufficient to create a significant treatment advantage at the tumor compared with the normal tissues. By creating an anti-CA19-9-PLN immunoconjugate, we can achieve "active targeting" through antibodyeantigen recognition, which may improve our tumor-specific delivery of therapeutic agents and minimize the bystander effects to normal cells from these cytotoxins. In such a way, we have the potential to deliver a cytotoxic payload to cancer cells in an antigen-specific manner.
